Work

PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

Year: 2012

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/s0923-7534(20)33038-6

Authors: P. Munster, R. van der Noll, E. Voest, J. Specht, T.L. Werner, E.C. Dees, A.R. Tan, A. Daud, J. Schellens, M.P. Lolkema, M. Griffin, N. Agarwal, G.S. Falchook, J.F. Kleha, M. Durante, D.A. Smith, L. Adams, J. Greshock, S.R. Morris, R. Kurzrock

Institutions: University of California, San Francisco, The Netherlands Cancer Institute, University Medical Center Utrecht, University of Washington, Fred Hutch Cancer Center, University of Utah, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Rutgers Cancer Institute, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, GlaxoSmithKline (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2999154618

FWCI: 1.281

Cites:

Cited by: 13

Related to: 10